Literature DB >> 33962838

The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.

Dominika A Kalkowska1, Arend Voorman2, Mark A Pallansch3, Steven G F Wassilak4, Stephen L Cochi4, Kamran Badizadegan1, Kimberly M Thompson5.   

Abstract

In early 2020, the COVID-19 pandemic led to substantial disruptions in global activities. The disruptions also included intentional and unintentional reductions in health services, including immunization campaigns against the transmission of wild poliovirus (WPV) and persistent serotype 2 circulating vaccine-derived poliovirus (cVDPV2). Building on a recently updated global poliovirus transmission and Sabin-strain oral poliovirus vaccine (OPV) evolution model, we explored the implications of immunization disruption and restrictions of human interactions (i.e., population mixing) on the expected incidence of polio and on the resulting challenges faced by the Global Polio Eradication Initiative (GPEI). We demonstrate that with some resumption of activities in the fall of 2020 to respond to cVDPV2 outbreaks and full resumption on January 1, 2021 of all polio immunization activities to pre-COVID-19 levels, the GPEI could largely mitigate the impact of COVID-19 to the delays incurred. The relative importance of reduced mixing (leading to potentially decreased incidence) and reduced immunization (leading to potentially increased expected incidence) depends on the timing of the effects. Following resumption of immunization activities, the GPEI will likely face similar barriers to eradication of WPV and elimination of cVDPV2 as before COVID-19. The disruptions from the COVID-19 pandemic may further delay polio eradication due to indirect effects on vaccine and financial resources.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  COVID-19 pandemic; Dynamic modeling; Polio

Year:  2021        PMID: 33962838     DOI: 10.1016/j.vaccine.2021.04.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Poliomyelitis amidst the COVID-19 pandemic in Africa: Efforts, challenges and recommendations.

Authors:  Olivier Uwishema; Emmanuel Ebuka Elebesunu; Oumnia Bouaddi; Arushi Kapoor; Samaa Akhtar; Fortune Benjamin Effiong; Adhiraj Chaudhary; Helen Onyeaka
Journal:  Clin Epidemiol Glob Health       Date:  2022-05-29

2.  Routine Immunization Programs for Children during the COVID-19 Pandemic in Ecuador, 2020-Hidden Effects, Predictable Consequences.

Authors:  Gianina Lizeth Suárez-Rodríguez; José Salazar-Loor; Jackson Rivas-Condo; Alfonso J Rodríguez-Morales; Juan-Carlos Navarro; José Rubén Ramírez-Iglesias
Journal:  Vaccines (Basel)       Date:  2022-05-27

3.  Impact of the SARS-CoV-2 pandemic on vaccine-preventable disease campaigns.

Authors:  Lee Lee Ho; Santosh Gurung; Imran Mirza; Hemanthi Dassanayake Nicolas; Claudia Steulet; Ashley L Burman; M Carolina Danovaro-Holliday; Samir V Sodha; Katrina Kretsinger
Journal:  Int J Infect Dis       Date:  2022-04-06       Impact factor: 12.074

4.  The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.

Authors:  Brent Burkholder; Zubair Wadood; Ahmed M Kassem; Derek Ehrhardt; Delayo Zomahoun
Journal:  Vaccine       Date:  2021-10-22       Impact factor: 3.641

5.  Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019-2023.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835

6.  SARS-CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling study.

Authors:  Simon R Procter; Kaja Abbas; Stefan Flasche; Ulla Griffiths; Brittany Hagedorn; Kathleen M O'Reilly; Mark Jit
Journal:  BMC Med       Date:  2021-08-12       Impact factor: 8.775

7.  Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama.

Authors:  Magda Rojas-Bonilla; Angela Coulliette-Salmond; Hanen Belgasmi; Kimberly Wong; Leanna Sayyad; Everardo Vega; Fabian Grimoldi; M Steven Oberste; Ricardo Rüttimann
Journal:  Viruses       Date:  2021-07-13       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.